- Yahoo!
- 20/8/30 17:05
The British drugmaker said Farxiga was shown in a study to cut the risk of dying from any cause for people suffering from chronic kidney disease by 31% when compared to a group on placebo. Farxiga is among AstaZeneca's five best-selling drugs and brought in revenues of $1.54 billion in 2019 for treating diabetes. It also reduced the risk of deteriorating kidney function by 39% in the...